News | Oncology Information Management Systems (OIMS) | April 25, 2019

Philips Unveils IntelliSpace Radiation Oncology at ESTRO 2019

Intelligent patient management solution on display to complement latest radiotherapy imaging and treatment planning innovations

Philips Unveils IntelliSpace Radiation Oncology at ESTRO 2019

April 25, 2019 – Philips announced IntelliSpace Radiation Oncology, an intelligent patient management solution to manage complexity, improve efficiency and enable operational excellence in radiotherapy departments. IntelliSpace Radiation Oncology, which is considered a work in progress and not available for sale, provides a harmonized way of working, integrating applications and automating workflow to help reduce the amount of time it takes from receiving a patient referral to the start of their treatment. The solution is being unveiled at the European Society for Radiation Oncology’s (ESTRO) 38th Annual Meeting, April 26-30 in Milan, Italy.

Radiotherapy is an important and cost-effective part of cancer treatment and control. More than half of all cancer types can be treated with radiotherapy [1], often in combination with other types of therapy such as surgery and chemotherapy. However, radiotherapy is often perceived as a complex treatment option due to the number of clinical specialists and advanced technologies required to deliver effective care. IntelliSpace Radiation Oncology is designed to manage this complexity by providing an integrated platform that connects all the steps from the patient’s referral to the start of their treatment.

The Philips platform is flexible and can be customized to the specific needs of a department and each clinician. It is an open, vendor-agnostic platform designed to provide comprehensive interoperability across the hospital information technology (IT) environment.

To support healthcare providers in capitalizing on the insights and workflow improvement opportunities presented by the platform, Philips is also launching Radiation Oncology Practice Management (also considered a work in progress and not available for sale). This consultancy service will support radiotherapy departments in identifying and acting on data-driven insights to achieve operational excellence.

IntelliSpace Radiation Oncology is the latest addition to Philips’ renewed suite of radiation oncology systems and software. On show for the first time at ESTRO, the new portfolio includes Pinnacle Evolution treatment planning software, Big Bore RT, a dedicated oncology computed tomography (CT) simulator, and the Ingenia Elition 3.0T MR-RT and Ambition 1.5T MR-RT magnetic resonance (MR) systems.

At the show Philips also announced that it plans to expand its MR-only radiotherapy simulation portfolio with MRCAT brain. Based on a single, fast MR scan and leveraging artificial intelligence (AI), Philips’ MRCAT brain will be designed to automatically generate CT-like density information on the MR console. Philips’ MR-only simulation technology, which also includes MRCAT pelvis and prostate, enables clinicians to rely on a single imaging modality by providing both MR’s superior soft-tissue contrast for delineation and density information for dose calculations. The solution is considered a work in progress, is not CE marked, and is not available for sale or distribution.

Philips is also highlighting its partnerships across imaging, planning and treatment support at ESTRO 38. In January 2019, the company announced a collaboration with imaging solutions provider MIM Software Inc., a company that provides practical imaging, automation and data analysis solutions to radiation therapy clinics worldwide. Philips also has an ongoing collaboration with Sun Nuclear to integrate its suite of PlanIQ software into Pinnacle Evolution.

Philips’ collaboration with Elekta has resulted in the introduction of the Elekta Unity, what it calls the world's first high-field MR-linac (linear accelerator). Philips also has a long-standing partnership with IBA, provider of proton beam therapy systems.

For more information: www.usa.philips.com/healthcare

 

References

[1] https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/basics.html

Related Content

Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Feature | Magnetic Resonance Imaging (MRI) | October 27, 2020
October 27, 2020 – Magn...
"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases was presented by Arjun Sahgal, M.D., University of Toronto, today at ASTRO20
News | Radiation Therapy | October 26, 2020
October 26, 2020 — A new study shows using fewer and higher doses of high-precision...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...